Cargando…

Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates

Background. There are few data on the combination of (pegylated-) interferon- (Peg-IFN-) α, ribavirin, and first-generation direct-acting antiviral agents (DAAs). Our aim was to describe the efficacy and safety of Peg-IFN-α, ribavirin, and boceprevir in hemodialysis patients. Patients. Six hemodialy...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehawej, Mireille, Rostaing, Lionel, Alric, Laurent, Del Bello, Arnaud, Izopet, Jacques, Kamar, Nassim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519545/
https://www.ncbi.nlm.nih.gov/pubmed/26257919
http://dx.doi.org/10.1155/2015/159795
_version_ 1782383509554331648
author Mehawej, Mireille
Rostaing, Lionel
Alric, Laurent
Del Bello, Arnaud
Izopet, Jacques
Kamar, Nassim
author_facet Mehawej, Mireille
Rostaing, Lionel
Alric, Laurent
Del Bello, Arnaud
Izopet, Jacques
Kamar, Nassim
author_sort Mehawej, Mireille
collection PubMed
description Background. There are few data on the combination of (pegylated-) interferon- (Peg-IFN-) α, ribavirin, and first-generation direct-acting antiviral agents (DAAs). Our aim was to describe the efficacy and safety of Peg-IFN-α, ribavirin, and boceprevir in hemodialysis patients. Patients. Six hemodialysis patients, chronically infected by genotype-1 HCV, were given Peg-IFN-α (135 µg/week), ribavirin (200 mg/d), and boceprevir (2400 mg/d) for 48 weeks. Results. At initiation of antiviral therapy, median viral concentration was 5.68 (3.78–6.55) log IU/mL. HCV RNA was undetectable in four of the six patients at week 4 and in all patients at week 24. A breakthrough was observed in two patients between weeks 24 and 48, and a third patient stopped antiviral therapy between weeks 24 and 48 because of severe peripheral neuropathy. At week 48, HCV RNA was undetectable in three patients. Of these, two patients relapsed within a month after antiviral therapy was stopped. Hence, only one patient had a sustained virological response; he was a previous partial responder. Overall, anemia was the main side effect. Conclusion. A triple antiviral therapy based on Peg-IFN-α, ribavirin, and boceprevir is not optimal at treating hemodialysis patients with chronic HCV infection. Studies using new-generation drugs are required in this setting.
format Online
Article
Text
id pubmed-4519545
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-45195452015-08-09 Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates Mehawej, Mireille Rostaing, Lionel Alric, Laurent Del Bello, Arnaud Izopet, Jacques Kamar, Nassim J Transplant Clinical Study Background. There are few data on the combination of (pegylated-) interferon- (Peg-IFN-) α, ribavirin, and first-generation direct-acting antiviral agents (DAAs). Our aim was to describe the efficacy and safety of Peg-IFN-α, ribavirin, and boceprevir in hemodialysis patients. Patients. Six hemodialysis patients, chronically infected by genotype-1 HCV, were given Peg-IFN-α (135 µg/week), ribavirin (200 mg/d), and boceprevir (2400 mg/d) for 48 weeks. Results. At initiation of antiviral therapy, median viral concentration was 5.68 (3.78–6.55) log IU/mL. HCV RNA was undetectable in four of the six patients at week 4 and in all patients at week 24. A breakthrough was observed in two patients between weeks 24 and 48, and a third patient stopped antiviral therapy between weeks 24 and 48 because of severe peripheral neuropathy. At week 48, HCV RNA was undetectable in three patients. Of these, two patients relapsed within a month after antiviral therapy was stopped. Hence, only one patient had a sustained virological response; he was a previous partial responder. Overall, anemia was the main side effect. Conclusion. A triple antiviral therapy based on Peg-IFN-α, ribavirin, and boceprevir is not optimal at treating hemodialysis patients with chronic HCV infection. Studies using new-generation drugs are required in this setting. Hindawi Publishing Corporation 2015 2015-07-16 /pmc/articles/PMC4519545/ /pubmed/26257919 http://dx.doi.org/10.1155/2015/159795 Text en Copyright © 2015 Mireille Mehawej et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Mehawej, Mireille
Rostaing, Lionel
Alric, Laurent
Del Bello, Arnaud
Izopet, Jacques
Kamar, Nassim
Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates
title Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates
title_full Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates
title_fullStr Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates
title_full_unstemmed Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates
title_short Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates
title_sort boceprevir-based triple antiviral therapy for chronic hepatitis c virus infection in kidney-transplant candidates
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519545/
https://www.ncbi.nlm.nih.gov/pubmed/26257919
http://dx.doi.org/10.1155/2015/159795
work_keys_str_mv AT mehawejmireille boceprevirbasedtripleantiviraltherapyforchronichepatitiscvirusinfectioninkidneytransplantcandidates
AT rostainglionel boceprevirbasedtripleantiviraltherapyforchronichepatitiscvirusinfectioninkidneytransplantcandidates
AT alriclaurent boceprevirbasedtripleantiviraltherapyforchronichepatitiscvirusinfectioninkidneytransplantcandidates
AT delbelloarnaud boceprevirbasedtripleantiviraltherapyforchronichepatitiscvirusinfectioninkidneytransplantcandidates
AT izopetjacques boceprevirbasedtripleantiviraltherapyforchronichepatitiscvirusinfectioninkidneytransplantcandidates
AT kamarnassim boceprevirbasedtripleantiviraltherapyforchronichepatitiscvirusinfectioninkidneytransplantcandidates